RGD Reference Report - Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists.

Authors: Ferrero, Hortensia  García-Pascual, Carmen M  Gaytán, María  Morales, Concepción  Simón, Carlos  Gaytán, Francisco  Pellicer, Antonio  Gómez, Raúl 
Citation: Ferrero H, etal., Fertil Steril. 2014 Nov;102(5):1468-1476.e1. doi: 10.1016/j.fertnstert.2014.07.1240. Epub 2014 Sep 11.
RGD ID: 13506956
Pubmed: PMID:25217874   (View Abstract at PubMed)
DOI: DOI:10.1016/j.fertnstert.2014.07.1240   (Journal Full-text)


OBJECTIVE: To explore whether a dopamine receptor 2 agonist (D2-ag) can prevent ovarian hyperstimulation syndrome (OHSS) in a rat model by decreasing ovarian vascular endothelial growth factor (VEGF) production.
DESIGN: Experimental study in an OHSS animal model.
SETTING: University-affiliated infertility center.
PATIENT(S): Immature Wistar rats.
INTERVENTION(S): Immature rats were stimulated with gonadotropins to mimic OHSS and treated with a D2-ag and/or D2-antagonists (D2-ant). Vascular permeability (VP) was measured at the endpoint, and ovaries were collected to assess the effects of these drugs on VEGF production.
MAIN OUTCOME MEASURE(S): VP was estimated by measuring the peritoneal extravasation of a previously injected dye. Ovarian VEGF mRNA expression and VEGF protein levels were assessed by quantitative real-time PCR and Western blots, respectively.
RESULT(S): The D2-ag exerted a reduction in VP that was associated with a drastic decrease in VEGF protein production in OHSS rat ovaries. The effects of this D2-ag on VP and VEGF protein levels were partially reversed by concomitant administration of a D2-ant. Ovarian VEGF mRNA expression levels were unaffected by these drugs in OHSS rats.
CONCLUSION(S): D2-ags prevent increased VP in OHSS rats by decreasing ovarian VEGF production, very likely through a D2-mediated post-transcriptional mechanism. Given the dose-dependent inhibitory effect of D2-ags on ovarian VEGF production reported herein, we infer that current OHSS therapies used in humans may be improved by increasing the intraovarian concentration of D2-ags in these patients.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
ovarian hyperstimulation syndrome treatmentISODrd2 (Rattus norvegicus)13506956; 13506956 RGD 
ovarian hyperstimulation syndrome treatmentIDA 13506956 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Drd2  (dopamine receptor D2)

Genes (Mus musculus)
Drd2  (dopamine receptor D2)

Genes (Homo sapiens)
DRD2  (dopamine receptor D2)


Additional Information